马海英, 赵宏, 焦顺昌, 史宏刚, 王志强, 司海燕. 高聚生联合化疗治疗结肠癌的近期疗效观察[J]. 中国肿瘤临床, 2006, 33(18): 1058-1060.
引用本文: 马海英, 赵宏, 焦顺昌, 史宏刚, 王志强, 司海燕. 高聚生联合化疗治疗结肠癌的近期疗效观察[J]. 中国肿瘤临床, 2006, 33(18): 1058-1060.
Ma Haiying, Zhao Hong, Jiao Shunchang, . Clinical Study on Colon Cancer Treated with Chemotherapy Combined with Highly Agglomerative Staphylococcin(HAS)[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2006, 33(18): 1058-1060.
Citation: Ma Haiying, Zhao Hong, Jiao Shunchang, . Clinical Study on Colon Cancer Treated with Chemotherapy Combined with Highly Agglomerative Staphylococcin(HAS)[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2006, 33(18): 1058-1060.

高聚生联合化疗治疗结肠癌的近期疗效观察

Clinical Study on Colon Cancer Treated with Chemotherapy Combined with Highly Agglomerative Staphylococcin(HAS)

  • 摘要: 目的 :观察高聚生联合化疗对结肠癌患者的肌体免疫调节作用。 方法 :68例结肠癌患者随机分为单纯化疗组和高聚生联合化疗组,单纯化疗组用奥沙利铂+亚叶酸钙+5-氟脲嘧啶持续静脉点滴方案,联合组在此基础上静脉点滴高聚生。化疗3个周期(9周)后复查CT评价疗效。 结果 :联合组的近期疗效高于单纯化疗组,具统计学差异(P<0.05);单纯化疗组患者经化疗后CD3+值较化疗前明显升高,而CD4+值及CD4+/CD8+比值较化疗前明显降低(P<0.05〉;化疗联合高聚生治疗组患者化疗前后的CD3+、CD4+值及CD4+/CD8+比值无显著差异;联合组的主要不良反应为发热和局部静脉炎。 结论 :高聚生联合化疗能克服化疗对机体的免疫抑制作用,提高结肠癌治疗的有效率。

     

    Abstract: Objective :To evaluate the efficacy of chemotherapy combined with highly agglomerative staphylococcin(HAS)for colon cancer. Methods :68 cases were randomized to receive chemotherapy combined with HAS(group A)and chemotherapy alone(group B).Oxaliplatin combined with FOLFOX4 was both used in two groups,and HAS was only used in group A. Results :The effect rate of group A Was higher than group B after 3 cycles(6 weeks)chemotherapy(P<0.05).Before chemotherapy in group B,CD3+was much higher,CD4+ and CD4+/CD8+ were obviously lower than those after chemotherapy(P<0.05).CD3+,CD4+ and CD4+/CD8+ had no significant difference before and after chemotherapy in group A.The major side effects were fever and phlebitis. Conclusion :HAS can reduce the immunosuppressive action caused by chemotherapy and enhance curative effect of colon cancer.

     

/

返回文章
返回